Zhan Yan, Liao Jin-Mao, Ye Ling, Zhang Long, Zhang Zheng, Yin Ji-Ye
Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
Hunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, Central South University, Changsha, China.
Front Pharmacol. 2025 May 21;16:1564124. doi: 10.3389/fphar.2025.1564124. eCollection 2025.
Idiosyncratic hepatotoxicity is a type of drug-induced liver injury (DILI) that is unpredictable and clinically severe, and amoxicillin clavulanate (AC) is the most implicated drug in DILI worldwide. The clinical manifestations of amoxicillin clavulanate-induced liver injury (AC-DILI) are fatigue and jaundice, which some allergic features may accompany, but autoimmune phenomena are uncommon. Here, we describe a special case report of a patient with AC-DILI accompanied by autoimmune phenomena for the first time. The patient was a middle-aged Chinese woman who developed liver damage after taking AC for a period of time, with a RUCAM score of 6. The patient tested positive for antinuclear antibodies and had elevated levels of IgG. Human leukocyte antigen (HLA)-targeted sequencing results showed that the patient did not carry known AC-DILI-related HLA polymorphisms, but Sanger sequencing suggested that the patient had the ERAP2 rs1363907 mutation, which may be a pathogenic factor of AC-DILI in the patient. The patient's progress notes, disease diagnosis, and treatment are summarized, and the role of ERAP2 pathogenic mutation rs1363907 in AC-DILI is discussed.
特异质性肝毒性是一种不可预测且临床严重的药物性肝损伤(DILI)类型,而阿莫西林克拉维酸(AC)是全球范围内DILI中最常涉及的药物。阿莫西林克拉维酸所致肝损伤(AC-DILI)的临床表现为疲劳和黄疸,可能伴有一些过敏特征,但自身免疫现象并不常见。在此,我们首次描述了一例伴有自身免疫现象的AC-DILI患者的特殊病例报告。该患者为一名中年中国女性,服用AC一段时间后出现肝损伤,RUCAM评分为6分。患者抗核抗体检测呈阳性,IgG水平升高。人类白细胞抗原(HLA)靶向测序结果显示,该患者未携带已知的与AC-DILI相关的HLA多态性,但桑格测序表明该患者存在ERAP2 rs1363907突变,这可能是该患者AC-DILI的致病因素。总结了该患者的病程记录、疾病诊断和治疗情况,并讨论了ERAP2致病突变rs1363907在AC-DILI中的作用。
Dig Dis Sci. 2016-8
Mayo Clin Proc. 2014-1
Curr Opin Gastroenterol. 2022-5-1
Eur J Gastroenterol Hepatol. 2024-2-1
Clin Gastroenterol Hepatol. 2023-7
Acta Pharm Sin B. 2022-12
Annu Rev Pharmacol Toxicol. 2022-1-6
Lancet Gastroenterol Hepatol. 2020-9